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ABSTRACT
The scaffold protein Spinophilin (Spinophilin, PPP1R9B) is one of the regulatory 
subunits of phosphatase-1 (PP1), directing it to distinct subcellular locations and 
targets. The loss of Spinophilin reduces PP1 targeting to pRb, thereby maintaining 
higher levels of phosphorylated pRb. Spinophilin is absent or reduced in approximately 
40% of human lung tumors, correlating with the malignant grade. However, little is 
known about the relevance of the coordinated activity or presence of Spinophilin and 
its reported catalytic partners in the prognosis of lung cancer. In the present work, 
we show that the downregulation of Spinophilin, either by protein or mRNA, is related 
to a worse prognosis in lung tumors. This effect is more relevant in squamous cell 
carcinoma, SCC, than in adenocarcinoma. Downregulation of Spinophilin is related 
to a decrease in the levels of its partners PPP1CA/B/C, the catalytic subunits of PP1. 
A decrease in these subunits is also related to prognosis in SCC and, in combination 
with a decrease in Spinophilin, are markers of a poor prognosis in these tumors. 
The analysis of the genes that correlate to Spinophilin in lung tumors showed clear 
enrichment in ATP biosynthesis and protein degradation GO pathways. The analysis 
of the response to several common and pathway-related drugs indicates a direct 
correlation between the Spinophilin/PPP1Cs ratio and the response to oxaliplatin and 
bortezomib. This finding indicates that this ratio may be a good predictive biomarker 
for the activity of the drugs in these tumors with a poor prognosis.
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INTRODUCTION
The Spinophilin (Spn, PPP1R9b) gene is located 
at 17q21.33, a cytogenetic area frequently associated 
with microsatellite instability and loss of heterozygosity 
(LOH). LOH in chromosome 17q21.3 has been observed 
in different tumors, including breast, ovarian, prostate, 
colorectal, gastric, renal and lung carcinomas as well as in 
salivary gland carcinosarcoma, an extremely aggressive 
neoplasm [1–6].
Low levels of Spinophilin expression have been 
found in lung adenocarcinoma [7], head and neck 
cancer [8], hepatocellular carcinoma [9], human gastric, 
small intestine and colorectal adenocarcinoma [10, 11], 
glioblastoma [12] and breast cancer [13, 14]. In all cases, 
downregulation of Spinophilin correlated with a higher 
malignant grade, more aggressive biological behavior and 
resistance to therapies, leading to faster relapse and poorer 
patient survival. Furthermore, the loss of Spinophilin also 
correlated with p53 mutations.
Analysis of human breast tumors showed that 
Spinophilin downregulation increased the stemness 
properties and the expression of stem-related genes 
(Sox2, KLF4, Nanog and OCT4) [14]. Breast tumor 
stem cells appeared to have low levels of Spinophilin 
mRNA, and Spinophilin loss correlated with increased 
stem-like cell appearance in breast tumors, as indicated 
by an increase in CD44+/CD24- cells. A reduction of the 
levels of PPP1CA mimicked the cancer stem-like cell 
phenotype of Spinophilin downregulation, suggesting 
that the mechanism of Spinophilin involves PP1a [14]. 
Spinophilin is a scaffolding protein interacting with more 
than 30 partner proteins, including protein phosphatase 1 
(PP1) and F-actin [15–17]. However, the physiological 
relevance of some of these interactions remains to be 
determined. Spinophilin performs important functions in 
the nervous system where it is implicated in regulating 
spine morphology and density, synaptic plasticity and 
neuronal migration [15]. Spinophilin also regulates seven-
transmembrane receptors and may link these receptors 
to intracellular mitogenic signaling events that are 
dependent on p70S6 kinase and the small G protein-GEF 
Rac. Spinophilin also interacts with doublecortin, an actin-
binding protein with an established role in the subcellular 
targeting of PP1. Spinophilin enhances PP1-mediated 
dephosphorylation of doublecortin [18] concomitant with 
PP1 localization in the cytosol [19, 20]. Thus, localization 
of the doublecortin–Spinophilin–PP1 complex in the 
cytosol inhibits PP1 phosphatase activity, leading to 
glioma cell death effects via a mitotic spindle catastrophe.
At the functional level, Spinophilin regulates 
PP1 activity, thereby maintaining higher levels of 
phosphorylated pRb [21]. This effect contributes to an 
increase in p53 activity through the increase in ARF 
protein. However, in the absence of p53, reduced levels 
of Spinophilin increase the tumorigenic properties of 
cells. Spinophilin knockout mice have a reduced lifespan, 
an increased number of tumors and increased cellular 
proliferation in some tissues, such as the mammary ducts. 
In addition, the combined loss of Spinophilin and p53 
activity in mouse models leads to an increase in mammary 
carcinomas, confirming the functional relationship 
between p53 and Spinophilin [22].
The data suggest that the regulation of PP1 activity 
is the mechanism by which Spinophilin acts to produce 
its tumor suppressor activity [23]. However, little is 
known about the relevance of the catalytic subunits of 
PP1 in cancer prognosis and specifically its coordinated 
regulation with Spinophilin.
PP1 serine/threonine phosphatases are multimeric 
enzymes assembled from a small number of catalytic 
subunits with one of hundreds of regulatory subunits. 
The regulatory subunit provides precision and specificity 
to the target [24]. These phosphatase regulators do not 
share extensive sequence conservation. Instead, they are 
identified by their physical interaction and function [24]. 
There are 4 different catalytic PP1 isoforms, PPP1CA/B/C, 
derived from 3 different genes, plus an alternate splicing 
of PPP1CC [25–27]. Due to the broad spectrum of activity 
of each catalytic subunit, not much information regarding 
their role in tumors or their pathological value has been 
published. In glioblastoma, PP1A protein expression 
showed no correlation with prognosis in all cases or 
on stratification based on IDH1 or ATRX expression. 
However, nuclear PP1A expression is a strong independent 
predictor of poor overall survival in p53-positive GBMs 
only [28]. PPP1CA urinary content was also associated 
with recurrence in bladder tumors [29]. Finally, analysis 
of human tumors suggests that one of the PPP1CA alleles 
might be lost in a high percentage of kidney and colorectal 
carcinomas [30].
Because the specificity and precision of each PPP1C 
isoform is given by the regulatory subunit and we detected 
downregulated Spinophilin in a subgroup of lung tumors, 
we investigated the effect of Spinophilin regulation of the 
PP1 catalytic subunits in human lung tumors.
RESULTS
Loss of Spinophilin in lung tumors
Spinophilin downregulation in human lung tumors 
is a causal event that triggers an increase in tumorigenic 
properties, contributing to their malignant status [7]. 
We have previously described [7, 10] that the cut off for 
downregulated or lower levels of SPINOPHILIN protein 
is equal or below 50% of the protein levels found in 
non-tumoral cells of the same tissue. Downregulation 
of SPINOPHILIN can be observed by immunostaining 
(Figure 1A) comprising around 30% samples. On the other 
hand, we quantified the levels of Spinophilin by mRNA 
expression levels and detected approximately 30% of 
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tumors with levels of Spinophilin lower than average (= 
0.0113) (Figure 1B). This percentage broadly correlated 
with the percentage of samples showing downregulation 
of Spinophilin by immunohistochemistry [7]. A more 
in-depth analysis using public transcriptomic databases 
shows a similar percentage of tumor samples with 
downregulated Spinophilin (Supplementary Figure 1). 
Furthermore, this downregulation of Spinophilin is more 
pronounced in squamous tumors than in adenocarcinoma 
(Figure 1C-1E).
A similar percentage of cases showed reduced 
Spinophilin levels independent of whether the analysis 
was performed on mRNA or protein, suggesting that 
Spinophilin downregulation occurs either by the loss of 
the 17p21 locus or in most cases through the regulation 
of mRNA levels. To further explore this result, we 
analyzed Spinophilin promoter methylation in matched 
lung tumor samples vs. non-tumoral samples from the 
same patient [31] (Supplementary Table 2). We found 
that this gene showed increased methylation in tumoral 
samples vs. non-tumor samples (Table 1). The increased 
methylation, however, occurs regardless of whether 
the samples are from adenocarcinoma or squamous 
carcinoma.
Figure 1: Loss of Spinophilin in human tumors. (A and B) Representative photo of different lung tumors with different Spinophilin 
levels. (C) The levels of Spinophilin mRNA in a cohort of 72 human lung tumors described in reference [7] were analyzed according to the 
procedure described in M&M. The mean value of mRNA levels of Spinophilin in all samples calculated and tumors distributed according to 
this mean value. High Spinophilin > mean value; Low Spinophilin > mean value. (D) Analysis of Spinophilin mRNA levels in samples from 
the cohort of [64]. (E) Analysis of Spinophilin mRNA levels in samples from the cohort of [65]. (E) Analysis of Spinophilin mRNA levels in 
samples from the cohort of [66]. In all three cases (D, E and F) the differences of the Spinophilin mRNA levels between ADC and SCC were 
statistically significant (p<0.05) ADC: Lung Adenocarcinoma; LCLC: Large Cell Lung Carcinoma; SCC: Squamous Cell Lung Carcinoma.
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Decreased Spinophilin levels predicted poor 
outcome in lung cancer patients
To evaluate whether SPINOPHILIN levels 
were associated with clinical outcome, we correlated 
SPINOPHILIN immunohistochemical staining with 
patient disease-free interval (DFI) and overall survival 
(OS). Decreased SPINOPHILIN levels were associated 
with a poorer OS (p=0,022) and DFI (P=0.020) in patients 
with lung cancer (Figure 2A and 2B). Multivariate analyses 
confirmed ECOG and stage as independent predictive 
factors for PFS. Regarding overall survival, only stage 
Table 1: Methylation of Spinophilin promoter in lung tumors
Spinophilin methylation NON-tumor Tumor Student’s T-test P value
Adenocarcinoma 0.44 (n=13) 0.52 (n=13) <0.0001
SCC 0.44 (n=10) 0.51 (n=10) 0.009
The data show the average mean of methylation (see Methods) in the analyzed samples (n=num of samples analyzed).
Figure 2: Survival probability of patients with lung cancer according to Spinophilin levels. (A) Overall survival (OS) and 
(B) Disease-Free Interval (DFI). (C) Overall survival (OS) and (D) Disease-Free Interval (DFI) in patients with low Spinophilin according 
to p53 levels.
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retained independent prognostic significance in the Cox 
multiple regression model (Supplementary Table 3). The 
analysis of concurrent molecular alterations showed a 
correlation with nuclear p53 staining [7]. Therefore, we 
measured the predictive value of SPINOPHILIN in human 
lung tumors with nuclear accumulation of p53 (Figure 2C 
and 2D). We found that low SPINOPHILIN correlated 
with high levels of nuclear p53 (>10%), as an indicator 
of mutant p53, and this pattern (low SPINOPHILIN and 
mutant p53) correlated with a worse prognosis in both OS 
and DFI (Figure 2C and 2D).
To further assess this hypothesis, we evaluated 
the association of Spinophilin mRNA levels with tumor 
response to patient survival in independent cohorts of 
publicly available databases (Supplementary Figure 
1). Low levels of Spinophilin mRNA in lung tumor 
tissue samples of different databases were always 
predictive of worse survival probability, correlating 
with the findings of immunohistochemistry on the 
SPINOPHILIN protein.
Consequently, low levels of Spinophilin mRNA 
were also associated with a shorter disease-free interval 
(DFI) and OS in these series of patients with lung tumors, 
highlighting the relevance of Spinophilin as a predictive 
factor (Figure 2 and Supplementary Figure 1).
Decreased levels of PPP1Cs are related with high 
risk and predicted poor outcome in lung SCC 
cancer patients
SPINOPHILIN is a regulatory subunit of PP1 and 
binds one of the catalytic subunits, PPP1CA, B or C, 
forming a heterodimer with PP1 phosphatase activity. 
Therefore, we measured whether the levels of these 
catalytic subunits are related to survival probability in 
tumors of the lung. To this end, we selected the TCGA 
databases for adenocarcinoma or SCC specific tumors. 
We observed that for adenocarcinoma, the patients with 
low levels of PPP1CA or B have a significantly higher 
risk of decreased survival than patients with high levels 
of expression of these genes (Figure 3A). The opposite 
effect is observed for PPP1CC. However, the survival 
probability of the patients does not change significantly 
when all three PPPC catalytic subunits are considered 
(Figure 3B).
When we studied SCC tumors, we observed a more 
homogeneous behavior and the patients with low levels 
of PPP1CA, B or C have a significantly higher risk than 
patients with high levels of these genes (Figure 3C). 
Furthermore, patients with low levels of these genes have 
a significantly poorer survival probability (Figure 3D).
Figure 3: Higher risk and lower survival probability of patients with lung cancer according to lower mRNA levels of the 
catalytic subunits of PP1. (A and C) Risk of worse survival probability according to mRNA levels in patients with adenocarcinoma (left, 
A) or squamous cell carcinoma (right, C). (B and D) Survival probability (log rank) of patients with lung cancer according to the mRNA levels 
of the joint catalytic subunits of PP1. Values were taken above or below the average for each subunit evaluated. High or low risks were taken 
according to the values of figure (A) and (C). (B) Lung adenocarcinoma; (D) Squamous cell carcinoma. The TCGA cohort was used.
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As a regulatory subunit, we studied the correlation 
of Spinophilin mRNA expression with those of the 
different catalytic subunits. We analyzed the levels of 
PPP1Cs mRNA in samples from Supplementary Table 
1. We detected a direct relationship between the levels of 
Spinophilin and those of each catalytic subunit (Figure 4A, 
Figure 4: Survival probability of patients with lung cancer according to the joint mRNA levels of the individual 
catalytic subunits of PP1 and Spinophilin. (A) Correlation between the mRNA levels of Spinophilin and the catalytic subunits of 
PP1 (Student’s T-test; ***=p<0.001). We analyzed the levels in a cohort of 70 samples from our cohort from Supplementary Table 1, for 
which we had mRNA (see Materials and Methods). We quantitated by Q-RT-PCR the levels of PPP1CA, PPP1CB and PPP1CC and plotted 
according to the low or high levels of Spinophilin mRNA (graph). The graph shows the distribution of the PP1 catalytic subunit according 
to the categorization of samples in high or low Spinophilin according to its average. Furthermore we plotted one to one correlation of 
PPP1CA/B/C mRNA levels to Sphinophilin mRNA levels in each sample. The index of correlation (r) and statistical significance (p) for 
the Pearson correlation is included in the inset in each graph. (B) Survival probability (log rank) of patients with lung cancer according to 
the mRNA levels of the joint individual catalytic subunits of PP1 and Spinophilin. Values were taken above or below the average for each 
subunit evaluated. High or low risks were taken according to the values of Figure 3A. The TCGA cohort was used.
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box graph was analyzed by Student’s T-test; inset also 
shows Pearson r). Therefore, we next measured whether 
the combination of regulatory Spinophilin and either of the 
catalytic subunits might have some predictive capability. 
We found that in adenocarcinoma tumors, the combination 
had no clear effect on survival prognosis (Figure 4B). 
However, the prognosis capability of low Spinophilin 
combined with low levels of PPP1CA/B or C is clearer in 
patients with SCC tumors of the lung (Figure 4B).
Finally, we combined low Spinophilin and low 
PPP1CA/B and C levels and analyzed the predictive 
capability of survival in patients with adenocarcinoma 
or SCC tumors. We observed a clear and significant poor 
prognosis in patients with tumors with low levels of 
combined Spinophilin/PPP1CA, B and C only in patients 
with SCC tumors (Figure 5).
While the analysis of the methylation of Spinophilin 
showed increased methylation, the analysis of PPPCs 
subunits methylation showed a decreased methylation 
mean, in tumors vs. non-tumor samples, in PPP1CA and 
PPP1CB, and increased methylation mean in PPP1CC 
(See Supplementary Table 4). Therefore, the mechanism 
of regulation must be different for all three isoforms. It 
may include transcriptional regulation or cell adaptation 
throughout the growth of the tumor.
Analysis of the GO terms correlating to 
Spinophilin
Patients with lung tumors with low Spinophilin 
levels showed clear and significant poor prognosis. 
Therefore, new therapeutic alternatives for these patients 
are needed. To explore this point, we looked for genes 
that correlated positively and negatively to Spinophilin 
(PPP1R9B) in the TCGA database. We selected genes 
with a correlation r>0.350 or r<-0.350, to identify genes 
that correlate positively or negatively to Spinophilin 
levels in tumors (Supplementary Table 5). Next, we 
identified the GO terms related to these genes using the 
Enrichr web portal (Supplementary Table 6A and 6B). 
The GO terms that correlated positively to Spinophilin 
were enriched in several biological processes, such as 
chromatin modification, ATP biosynthetic processes, 
embryo development and the regulation of GTPase 
activity (Figure 6). Alternatively, GO terms that correlated 
negatively to Spinophilin, and therefore may be enriched 
in tumors with low Spinophilin, were the regulation of 
protein degradation, ATP biosynthetic processes and the 
regulation of the cell cycle (Figure 6).
These GO term enrichment assays suggest that 
several pathways interfere with the aim of finding 
alternative therapies. Processes such as the regulation of 
protein degradation, ATP biosynthetic processes and the 
regulation of the cell cycle being negatively correlated 
seemed more suitable because they are altered in the 
absence of Spinophilin. Therefore, we tested the effect of 
metformin, a regulator of the ATP biosynthetic process, 
and bortezomib, an inhibitor of protein degradation, in 
a panel of lung cancer cell lines and their correlation to 
Spinophilin.
Analysis of the correlation between Spinophilin 
and PPP1Cs in a panel of lung cancer cell lines 
and their relationship with the drug response
First, we analyzed the levels of expression of 
Spinophilin in a panel of 17 lung cancer cell lines 
(Supplementary Table 7), and we observed a different 
pattern of expression (Figure 7A). Therefore, we classified 
the panel as high Spinophilin cell lines (H1437, H1781, 
Figure 5: Survival probability of patients with lung cancer according to the joint mRNA levels of the catalytic subunits 
of PP1 and Spinophilin. Survival probability (log rank Cox) of patients with lung cancer according to the mRNA levels of the joint 
catalytic subunits of PP1 and Spinophilin. Values were taken above or below the average for each subunit evaluated. High or low risks were 
assessed according to the values of Figure 3A. The TCGA cohort was used.
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H2009, H358, Calu3 and Nuli1) and low Spinophilin cell 
lines (H1650, H1975, H2228, H226, H3122, H460, H520, 
HCC827, Calu1, A549 and NL20).
Then, we studied the correlation of Spinophilin 
expression with those of the different catalytic subunits 
in the panel of 17 different lung cancer cell lines 
(Supplementary Table 8). As in the case of tumors, 
we detected a direct relationship between the levels 
of Spinophilin and the levels of each catalytic subunit 
(Figure 7B, inset shows also Pearson r; Supplementary 
Table 8). As in tumors, cell lines with low Spinophilin also 
contained low levels of each catalytic subunit.
With the aim of finding a drug that may be active in 
lung cell lines with low Spinophilin levels, we subjected 
this panel of 17 cell lines to different treatments to obtain 
the IC50 for the response in each cell line (Supplementary 
Table 9). We specifically tested cisplatin and etoposide as 
common treatments for lung tumors as well as oxaliplatin 
as a platinum-derived compound with a different 
spectrum of activity. Finally, we also tested metformin 
as a modulator of ATP biosynthesis and bortezomib as an 
inhibitor of proteasomal degradation [32, 33] because these 
two mechanisms seemed to be highly related to genes that 
correlated to Spinophilin levels. Then, we correlated the 
IC50 for each drug with the levels of Spinophilin, PPP1Cs 
or the ratio among them and calculated the correlation 
index (Pearson r). We found that none of the activities 
of these drugs correlated with the levels of expression of 
any of the tested genes individually (Table 2). However, 
we found a clear correlation between the ratio between 
Spinophilin and PPP1CA or PPP1CB and the activity of 
oxaliplatin or bortezomib (Table 2, Supplementary Figure 
2). Alternatively, we did not observe a correlation between 
metformin activity and Spinophilin or PP1 values.
These data suggest that the lower ratio between the 
levels of expression of these genes may be a good marker 
for the response to oxaliplatin or bortezomib. Therefore, 
tumors with lower levels of Spinophilin might respond 
better to oxaliplatin and/or bortezomib depending on the 
levels of PPP1CA/B. However, this functional hypothesis 
needs more research and to be validated in animal models.
DISCUSSION
Downregulation of Spinophilin, either in protein or 
mRNA, is related to worse prognosis in lung tumors. This 
effect is more relevant in squamous cell carcinoma than in 
adenocarcinoma. Downregulation of Spinophilin is related 
to a decrease in the levels of PPP1CA/B/C, the catalytic 
subunits of PP1 and partners of Spinophilin. A decrease 
in these subunits is also related to a poor prognosis in 
SCC and is observed more clearly in combination with 
Figure 6: GO term enrichment by genes that correlate positively or negatively to Spinophilin levels. The analysis by the 
Enrichr portal was performed on the genes from Supplementary Table 5. The genes were obtained by R2 analysis in data from the TCGA 
database.
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a decrease in Spinophilin. PP1 has been identified as the 
major enzyme that dephosphorylates pRb during mitosis 
[34, 35] and plays an important role in the G1/S transition 
[36]. Although there is literature supporting the role of 
PP1 regulation of pRb in vivo [37–39], our work is the 
first to support the downregulation of the components of 
the PP1 heterodimer as a direct contribution to lung cancer 
and as a predictor of a worse prognosis for these patients.
Figure 7: Correlation between the mRNA levels of Spinophilin and the catalytic subunits of PP1 in a panel of tumor 
cell lines. We analyzed a cohort of 17 cell lines described in Supplementary Table 7. (A) We analyzed the expression levels of Spinophilin 
in the cohort of 17 cell lines described in Supplementary Table 3. We divided the panel into high and low Spinophilin, considering high 
Spinophilin those cell lines with expression > 0.01: H1437, H1781, H2009, H358, Calu3 and Nuli1 cell lines; and low Spinophilin the ones 
with expression < 0.01: H1650, H1975, H2228, H226, H3122, H460, H520, HCC827, Calu1, A549 and NL20 cell lines. (B) We detected 
a direct relationship between the levels of Spinophilin and the levels of each catalytic subunit. The graph shows the distribution of the PP1 
catalytic subunit according to the categorization of samples with high or low Spinophilin according to its average. We considered high 
Spinophilin: H1431, H1781, H2009, H358, Calu3 and Nuli1 cell lines, and low Spinophilin: H1650, H1975, H2228, H226, H3122, H460, 
H520, H827, Calu1, A549 and NL20 cell lines. Furthermore, the inset shows Pearson’s r and its statistical significance.
Table 2: Pearson correlation (r) between the IC50 of the different treatments and the levels of the indicated genes






metformin -0.2567736 -0.0305505 0.0471795 0.0072612 -0.1737827 -0.2997706 -0.3934922
oxaliplatin 0.1098795 -0.0758366 -0.2116024 0.2138328 0.5907283 0.6886702 0.0679746
cisplatin 0.0367228 0.06338384 0.0771211 -0.1303417 -0.1979426 -0.1891476 -0.0018704
etoposide 0.0134608 -0.0350167 -0.0008127 -0.0196913 -0.0707570 -0.0349190 -0.0275979
bortezomib -0.0652384 -0.3027230 -0.0553075 0.2275598 0.7996544 0.4329986 0.0972166
* indicates the ratio between the levels of Spinophilin and the catalytic subunit indicated.
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Along with lung tumors [7], Spinophilin mRNA and/
or proteins are lost in a percentage of different neoplasias 
[23]. Spinophilin levels were also associated with high 
proliferative recurrences and poor patient prognosis in 
hepatocarcinoma, head and neck cancer and advanced 
stages of colorectal carcinoma [8-11]. Furthermore, 
lower levels of Spinophilin mRNA correlated with a 
higher grade of renal carcinomas, ovarian carcinoma and 
chronic myelogenous leukemia [23]. In human breast 
tumors, Spinophilin is lost or reduced in approximately 
15% of samples, correlating with higher grade and more 
aggressive neoplasms [14]. Spinophilin loss correlates 
with a higher level of a putative CSC-like phenotype [11, 
14].
Spinophilin regulates PP1 activity [40], and the 
loss of Spinophilin reduces the phosphatase activity of 
PP1a on its target pRb [41], thereby maintaining higher 
levels of phosphorylated pRb and inducing an increased 
proliferative response [21]. The pRb pathway controls 
several aspects of stem cell biology, including the tight 
control of self-renewal characteristics of progenitor cells 
[42, 43]. It has been suggested that relapse and poor 
response to chemotherapy is related to the number of 
CSCs [44]. The fact that the loss of Spinophilin increases 
the stem-like properties of tumor cells may explain 
its association with more aggressive tumors and poor 
response in patients.
It is remarkable that PPP1CA downregulation 
mimics the effect of Spinophilin downregulation, 
increasing the proportion of cancer-initiating cells, 
suggesting that cells with low PP1 phosphatase activity are 
characterized by aggressive features and may encompass 
a higher percentage of precursors than the putatively less 
aggressive counterparts [44]. These results fully support 
those of Dedinszki et al., who showed that inhibition of 
protein phosphatase-1a decreases the chemosensitivity of 
leukemic cells to chemotherapeutic drugs [45].
The loss of pluripotency and stemness is associated 
with the activation of pRb, which determines the 
transcription of E2F-dependent genes [42]. Because pRb 
activity is directly regulated by the PP1 heterodimer 
studied in this work, there is the possibility that some 
of the clinical properties observed in vivo may be due 
to the pRb activity regulating cancer stemness [43]. 
Additionally, consistent with our results, Spinophilin 
can restrain the self-renewal of brain tumor-initiating 
cells [46] and anchorage-independent growth of glioma 
cell lines [47]. In addition to the PP1 regulatory activity 
of Spinophilin on pRb phosphorylation, Spinophilin 
has other targets, such as doublecortin, an actin-binding 
protein with an established role in the subcellular targeting 
of PP1 [17, 48]. Spinophilin enhances PP1-mediated 
dephosphorylation of the PSer297 site of doublecortin 
[20]. Doublecortin is a microtubule-binding protein that 
induces growth arrest at the G2–M phase of the cell 
cycle in glioma cells and suppresses tumor xenograft 
growth in a Spinophilin-dependent manner, which occurs 
concomitantly with PP1 localization into the cytosol 
[47]. Doublecortin significantly reduces self-renewal of 
brain tumor stem cells in human primary glioma cells 
from surgically removed human glioma specimens and 
glioma cells in vitro and in vivo [46]. This effect on the 
restriction of self-renewal of brain tumor-initiating cells 
appears dependent on Spinophilin expression [46]. To 
what extent there are two independent effects, on pRb and 
doublecortin or additive or synergistic effects, should be 
further studied.
According to the expression data provided by the 
Project: HPA RNA-seq normal tissues where RNA-
seq was performed of tissue samples from 95 human 
individuals representing 27 different tissues in order to 
determine tissue-specificity of all protein-coding genes 
[49]. All three isoforms are ubiquitously expressed, but 
with some variation in the levels according to the different 
tissue analyzed. PPP1CA mRNA is mainly found in cells 
of the gastro-intestinal organs, bone marrow, spleen, 
lymph node and bladder; PPP1CB mRNA is mainly 
found in cells from prostate, heart and endometrium. 
PPP1CC mRNA is mainly found in cells from the gastro-
intestinal organs and testis. The catalytic subunits may 
be functionally equivalent biochemically, however, since 
the specificity on the effector is given by the regulatory 
proteins, the later are the ones conferring different 
functionality to PP1 heterodimers on cells.
While the analysis of the methylation of Spinophilin 
showed increased methylation, the analysis of PPPCs 
subunits methylation showed a decreased methylation 
mean, in tumors vs. non-tumor samples, in PPP1CA and 
PPP1CB, and increased methylation mean in PPP1CC. 
Therefore, the mechanism of regulation must be different 
for all three isoforms. Combined to the data of Spinophilin, 
it indicates that the regulation of the heterodimer of PP1 
is not homogeneous by methylation. These data further 
suggests that the combined co-regulation of PPPCs and 
the regulatory subunit Sphinophilin may include strong 
transcriptional regulation or cell adaptation throughout 
the growth of the tumor. This is an interesting point that 
should be further explored.
Because phosphatase regulators exist in a molar 
excess to PPP1Cs [50], how the downregulation of one 
single regulator protein, even partial, such as Spinophilin, 
triggers such important regulatory effects leading to 
cancer is unknown. We can argue that it is the specific 
effector of PP1 targeted by the regulator that is truly the 
key point of the effect. Alternatively, PPP1Cs recruitment 
is associated with the folding of the regulators, and it 
can be hypothesized that some PP1 functions may be 
independent of its enzymatic activity and involve some 
type of chaperone function [50].
Other regulators targeting similar components, such 
as PPP1R12a (MYPT1), are also downregulated in tumors 
[51, 52] but have no effect on patient survival with lung 
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tumors nor alter the effect of the partner catalytic subunits 
(data not shown).
Finally, in a panel of lung cancer cell lines, 
the analysis of the response to several commonly 
used drugs indicates a direct correlation between the 
Spinophilin/PPP1C ratio and the response to oxaliplatin 
or bortezomib. This finding indicates that this ratio 
may be a good marker for the activity of these drugs in 
tumors with a poor prognosis. Spinophilin-correlating 
genes and GO-related networks suggest a relationship 
to the ubiquitin degradation pathway with Spinophilin, 
which may explain this effect. However, although we 
found some relationship to DNA repair components, 
it is difficult to differentiate the positive effect of 
oxaliplatin from that not responding to cisplatin 
or etoposide. It will also be interesting to test the 
relationship of Spinophilin levels to cell cycle inhibitors 
or chromatin modifiers also according to the results of 
the GO enrichments.
In summary, our data show for the first time that 
the protein Spinophilin has prognostic and predictive 
value for lung cancer. Interestingly, we observed certain 
co-regulation between Spinophilin and the catalytic 
subunits of PP1. The low levels of these subunits also have 
prognostic and predictive value, especially in squamous 
cell lung carcinoma, and the combination of low levels 
of Spinophilin+PPP1Cs has stronger prognostic value. 
Finally, in a panel of lung cancer cell lines, the analysis 
of the response to several commonly used drugs indicates 
a direct correlation between the Spinophilin/PPP1C 
ratio and the response to oxaliplatin or bortezomib. This 
finding indicates that this ratio may be a good marker 




The study was performed in 2 different cohorts.
The first cohort comprises a group of 245 NSCLC 
patients from Virgen del Rocío Hospital. All samples 
were collected from 2007–2009. This cohort is reported 
in Supplementary Table 1. No patients were treated with 
chemotherapy or radiotherapy before surgical resection. 
Written informed consent was obtained from all of the 
patients, and the Ethical Committee of the Hospital 
involved approved the study. All of the samples were 
treated according to the Helsinki guidelines for research 
regarding human samples. From this cohort we generated 
a tissue microarray that was stained for Spinophilin and 
p53 protein levels. These data was used in Figures 1A 
and 2. From this cohort, we could obtain mRNA from 
a subgroup of 72 patients only. The mRNA from this 
subgroup was only used for the quantitative experiments 
of Figures 1B and 4A.
The second cohort, described in the Supplementary 
Table 2, contains 70 DNA samples from, 47 patients 
not included in the first cohort. It was composed of 23 
matched tumor and non-tumor samples from the same 
patient, plus 24 non-matched tumor samples from different 
patients. In total, only 47 patients composed the second 
cohort. The clinical features of patients with NSCLC of 
this cohort are summarized in Supplementary Table 2. The 
samples were obtained from patients following surgical 
resection mostly for clinical early stage NSCLC, but also 
included 10 samples from stages III and IV. A description 
of this cohort can also be found in the literature [53]. 
During the surgical procedure, the tumor and matched 
non-tumor tissue samples were collected from patients 
and then immediately snap-frozen at −80°C for future use. 
The methylation profiles of Spinophilin and PPCs were 
evaluated in tumoral and non-tumoral tissue. A written 
consent form was obtained from all participants. The study 
protocol and the use of human samples were approved by 
the Ethical Committee of the Virgen del Rocio University 
Hospital.
DNA samples
Genomic DNA was extracted from tumor and 
matched non-tumor tissue samples by the QIAamp 
DNA mini kit (QIAGEN, Valencia, CA, USA). DNA 
was quantified using the QuantiFluor dsDNA system 
(Promega, Madison, WI, USA) according to the 
manufacturers’ instructions.
Illumina 450 K methylation
The Illumina Infinium Human Methylation 450 
BeadChip (Illumina Inc., San Diego, CA, USA) was used 
to interrogate 485,000 methylation sites across the genome 
per sample at single-nucleotide resolution. It covers 96% 
of the CpG islands, with additional coverage in island 
shores and the flanking regions. We treated 500 ng of DNA 
with sodium bisulfate using the EZ DNA Methylation™ 
Kit and cleaned the DNA with the ZR-96 DNA Clean-
up Kit™ (EZ DNA, Zymo Research, Irvine, CA, USA) 
before standard Illumina amplification, hybridization, and 
imaging steps. The resulting intensity files were analyzed 
with Illumina’s GenomeStudio, which generated β-scores 
(i.e., the proportion of total signal from the methylation-
specific probe or color channel).
Methylome data processing
Methylome data were processed using the RnBeads 
R package [54]. After a quality check, the probe median 
intensity was normalized with the SWAN method [55] 
and converted to beta values. The probes were tested 
for differential methylation with the limma method, a 
linear model followed by empirical Bayes methods for 
the comparisons of interest [56]. The CpG status (hypo- 
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versus hyper-methylated) and CpG chromosomal location 
were realized using the Circos data visualization software 
[57].
Analysis of gene transcription
Total RNA was purified using an RNeasy Kit 
(QIAGEN) and reverse transcription into cDNA was 
performed with 3 μg of mRNA using the High-Capacity 
cDNA Reverse Transcription Kit (Life Technologies) 
according to the manufacturer’s recommendations. Real-
time PCR was performed with an Applied Biosystems 
7900HT cycler using the GoTaq® Probe qPCR 
Master Mix (Promega), following the manufacturer’s 
recommendations. The thermocycler parameters were 
95°C for 10 min followed by 40 cycles of 95°C for 15 
s and 60°C for 60 s. We used the following TaqMan 
gene-specific probes from Life Technologies: PPP1R9B 
(Hs00261636_m1), PPP1CA(Hs00267568_m1), PPP1CB 
(Hs01027793_m1), PPP1CC (Hs00160351_m1), and 
GAPDH (Hs03929097_g1). We used the housekeeping 
gene GAPDH to normalize the RNA amount. Relative 
changes in gene expression levels were calculated using 
the comparative threshold cycle (ΔΔCt) method. At least 
three independent experiments were performed for each of 
the analyzed genes. Student’s t-test was applied for each 
pair of samples, with a significance threshold of p < 0.05.
Immunohistochemistry
Immunohistochemistry analysis was performed 
as previously described [58–60]. The primary antibody 
(Anti-Spinophilin: ab5669 from Merck Millipore) was 
incubated overnight at 4°C as previously described [58, 
61, 62]. A secondary anti-rabbit antibody (JI-111-035-
003) was applied for 1 hour at room temperature and 
revealed using substrate buffer and chromogen (Envision, 
Flex DAKO). The tissues were counterstained with 
hematoxylin (DAKO), rehydrated in a graded alcohol 
series, and mounted using coverslips. These procedures 
were performed at the Histopathology Unit at the IBIS.
Retrospective analysis of gene expression in 
human tumors
Correlations between grade, patient survival, tumor 
recurrence and Spinophilin and PPP1CA/B/C gene 
expression were determined through analysis of French 
(GSE16011), TGCA, French-Core Exon (GSE43107), 
Sun Brain (GSE4290) and Freije (GSE4412) datasets, 
respectively, which are available through Oncomine 
(Compendia Biosciences, w) and R2: Genomics 
analysis and visualization platform (http://r2.amc.nl/). 
High and low groups were defined as above and below 
the mean, respectively. To analyze the high and low 
groups, high was defined as greater than one standard 
deviation above the mean, and low was greater than one 
standard deviation below the mean. The National Cancer 
Institute’s Repository for Molecular Brain Neoplasia Data 
(REMBRANDT, http://rembrandt.nci.nih.gov) was also 
evaluated for correlations between patient survival and 
gene expression with up- or downregulation being defined 
as a 2-fold change relative to mean values. Multigene 
analysis of Kaplan-Meier (Cox regression) curves was 
performed through the SurvExpress Genomics analysis 
and visualization platform [63].
Statistical analysis
All grouped data are presented as the mean ± 
standard error. The difference between groups was 
assessed by ANOVA or Student’s t-test using GraphPad 
Prism software. For survival analysis, Kaplan-Meier 
curves were generated using Prism software and R2 
Kaplan-Meier plotting service and log rank analysis 
was performed. All experiments were repeated in each 
condition at least twice with triplicate technical replicates. 
The data distribution was assumed to be normal but 
was not formally tested. Data obtained for retrospective 
analysis were collected and processed in the appropriate 
experimental arms.
Multivariate analysis was performed with the 
Cox proportional hazards method. In these analyses, 
overall survival (OS) and progression free survival 
(PFS) were defined as the time from diagnosis to exitus 
and progression, respectively. P<0.05 was considered 
significant. All analyses were performed using the 
Statistical Package for the Social Sciences software (SPSS 
17.0 for Windows; SPSS Inc, Chicago, IL, USA).
Cell lines
Two immortalized lung epithelial cell lines (NuLi-
1 and NL-20), 4 lung SCC cell lines (Calu-1, HTB59, 
H520 and H226) and 12 lung ADC cell lines were used 
(Supplementary Table 3). All cell lines were purchased 
from the ATCC before the beginning of this work, with 
the exception of H1437 and H3122, which were kindly 
provided by Dr. Maina and Dr. Koivunen, respectively. No 
further authentication was performed in these cell lines. 
All cell lines were culture in RPMI 1640 medium (Sigma), 
except for Calu-1, which was cultured in McCoy’s 5A 
medium (Gibco) and Calu-3 in DMEM medium (Sigma), 
supplemented with 10% fetal bovine serum (FBS) at 37 °C 
under a 5% CO2 atmosphere. All cell lines were regularly 
tested for mycoplasma.
MTT assay
For the assay, 5x103 cells were seeded and then 
treated with the different compounds (oxaliplatin, 
cisplatin, etoposide, metformin and bortezomib) at 11 
Oncotarget105208www.impactjournals.com/oncotarget
different concentrations at 1/3 after 24 hours. Then, 96 
hours later, cell viability was measured via MTT assay.
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